Profusa Announces Listing Transfer to The Nasdaq Capital Market
Rhea-AI Summary
Profusa (Nasdaq: PFSA), a digital health company focused on continuous biochemical monitoring, announced that effective May 15, 2026, its shares are listed on The Nasdaq Capital Market.
This transfer is the first in a series of interim milestones set by a Nasdaq Hearings Panel to support continued compliance with bid price and stockholders’ equity listing requirements.
Positive
- Shares now listed on The Nasdaq Capital Market as of May 15, 2026
- Defined interim milestones support efforts to maintain Nasdaq listing compliance
Negative
- Company subject to Nasdaq Hearings Panel milestones for listing compliance
- Ongoing need to meet bid price and stockholders’ equity requirements
News Market Reaction – PFSA
In the May 15 session, PFSA gained 3.66%, reflecting a moderate positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 08 | Nasdaq listing decision | Positive | +5.3% | Nasdaq Hearings Panel granted transfer to the Nasdaq Capital Market. |
| May 05 | Strategic review launch | Neutral | -6.6% | Board began evaluating strategic alternatives and PanOmics asset purchase. |
| Apr 06 | PanOmics LOI | Positive | +144.1% | LOI to acquire PanOmics diagnostics platform for equity consideration. |
| Feb 27 | Offering withdrawn | Neutral | -14.8% | Company withdrew a planned $15M S-1 offering to pursue a smaller deal. |
| Feb 19 | Guidance raised | Positive | -4.5% | Received Lumee orders and raised 2026 revenue guidance to $1.5M–$3.0M. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
PFSA has shown mixed reactions to operational and listing-related updates: some positive corporate milestones led to sharp gains, while other seemingly constructive announcements coincided with negative or muted moves.
Over the last six months, PFSA announced several key steps: a Feb 19 update on Lumee purchase orders and higher 2026 revenue guidance, a Feb 27 decision to withdraw a $15M S-1 offering, and an early April LOI for a $30M PanOmics platform that saw a strong positive price reaction. In early May, PFSA disclosed a strategic alternatives review and then a favorable Nasdaq determination allowing transfer to the Capital Market, with today’s news formalizing that listing move.
Key Terms
nasdaq capital market regulatory
nasdaq hearings panel regulatory
bid price financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BERKELEY, CA, May 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a digital health company pioneering the next generation of technology platform enabling the continuous monitoring of an individual’s biochemistry, announces that, effective May 15, 2026, the Company will now be listed on The Nasdaq Capital Market.
The move is the first of a previously announced series of interim milestones as laid out by the Nasdaq Hearings Panel to ensure continued compliance with the bid price and stockholders’ equity requirements for continued listing on the Capital Market tier.
About Profusa
Based in Berkeley, CA, Profusa is a commercial stage digital health company led by visionary scientific founders, an experienced management team and a world-class board of directors in the development of a new generation of tissue-integrated sensors to detect and continuously transmit actionable, medical-grade data for personal and medical use. With its long-lasting, injectable and affordable biosensors and its intelligent data platform, Profusa aims to provide people with a personalized biochemical signature rooted in data that clinicians can trust and rely on.
“LUMEE”, “PROFUSA” and the PROFUSA logo are registered trademarks of Profusa, Inc. in the United States, Canada, European Union, China, Japan, South Korea and Australia.
For more information, visit https://profusa.com.
Special Note Regarding Forward-Looking Statements
Certain statements in this press release may be considered “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or future financial or operating performance of Profusa. In some cases, you can identify forward-looking statements by terminology such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “future,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “propose,” “seek,” “should,” “strive,” “will,” or “would” or the negatives of these terms or variations of them or similar terminology. Forward‑looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those described in such statements, including but not limited to the Company’s ability to obtain the required stockholder approvals, execute its compliance plan within the timeframes specified by the Panel, effect and maintain compliance with the Bid Price Rule and other applicable listing requirements, complete anticipated transactions, and other factors described in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including its Annual Report on Form 10‑K for the year ended December 31, 2025, and subsequent Quarterly Reports on Form 10‑Q and Current Reports on Form 8‑K. The Company undertakes no obligation to update any forward‑looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contacts
Investor and Media Contacts
email: info@coreir.com
phone: 1 (212) 655-0924
